A Study to Evaluate Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Surgical Resection or Ablation

Condition:   Hepatocellular Carcinoma (HCC) Interventions:   Drug: Camrelizumab;   Drug: Apatinib Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials